Waters | Wyatt Technology’s Post

Save the date! On July 18th join scientist Leo Liu for the "Episode 6: USP Chapter 129 Updates and SEC-MALS" webinar. This event, in collaboration with Waters Corporation and US Pharmacopeia, promises valuable insights into SEC-MALS. Don't miss it! #Webinar #SECMALS #PharmaceuticalScience #USPharmacopeia #WatersCorporation

The 6th Targeted Radiopharmaceuticals Europe Team (December 3-5 | Amsterdam) brings you insights captured from Beacon Intelligence. Full Event Guide: https://ter.li/3z3ypq Register: https://ter.li/xji1ty -> The PSMA space is getting crowded, with 60 radiopharmaceutical therapeutic assets in development right now -> Highly potent radioactive payloads mean there has been growing interest for stromal target, Fibroblast Activation Protein (FAP) with 26 assets in development ->There are seven targets which have between 5-10 assets in development including DLL3 (Shared by Molecular Partners - Orano Med), B7-H3, c-MET and others -> 75 targets have less than 5 active assets, including CA9, LAT1 and P-Cadherin #radiopharmaceuticals #TRP

KOR-Gi/o protein selectivity -towards the development of G protein subtype targeted therapeutics Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox ➡️https://bit.ly/3YoTJTf #gpcr #drgpcr

In process development workflows, which often refer to the development of a bioprocess for the production of e.g., therapeutic antibodies, the accurate, rapid, and high-throughput measurement of immunoglobulins, particularly immunoglobulin G (IgG), is essential to screen for productivity and to ensure the development of optimized and high-value processes. The Valita Titer Assay can help to enhance this process development workflow through rapid and easy IgG titer quantification by supporting: ✔️early-stage evaluation ✔️optimization of culture conditions ✔️scale-up/down assessment ✔️process robustness evaluation ✔️process troubleshooting Learn about the importance of accurate and high-throughput IgG quantification for process optimization and scale-up with the Valita Titer assay: https://becls.co/3H6PZfj #beckmancoulterlifesciences #valitacell #clonesscreening #mAbs #titer #CHO #processoptimization

The 5-year survival rate for patients with AML is 28.7%. One sponsor sought to bring better treatment through its targeted monoclonal antibody therapy, and we were there to help accelerate approval. See how: https://bit.ly/3STTyfS #PatientCentricity #ImmunoOncology #RegulatoryStrategy #NonClinical #ClinicalPharmacology #CancerTreatment

Aggregation presents a significant challenge in bioprocessing, particularly for the production of therapeutic proteins and monoclonal antibodies.  https://lnkd.in/ezJfKYdG    #ScientistsEnablingScientist #ADC #Services #Bioprocess #Biomanufacturing

At Pomona our primary focus lies in the pre-clinical characterization stage, a pivotal phase that sets the foundation for successful drug development. Learn more on your website: #pomona #reserch #preclinical #pipeline #drugdevelopment #monoclonalantibody

▶️🖱️ Now available on-demand! Watch our webinar featured on Scientist.com on the Applications of Humanized Mice in the Evaluation of Antibody-Drug Conjugates to Treat Autoimmune Diseases! 👉 Click here to watch: https://buff.ly/3yGYTiT This webinar features our Director of Scientific Engagement, Dr. Jun Wang, and BioRay Pharmaceutical's President, Dr. Gang Chen. Key topics include: ☑️ Advantages of using humanized mouse models to evaluate ADCs ☑️ Applications of humanized mice to evaluate ADCs in autoimmune disease models ☑️ The design and screening of the Linker-Payloads of Bioray’s Immune modulating ADC (ImADCTM) #adcs #antibodydrugconjugates #autoimmune #mousemodels https://buff.ly/3yGYTiT

𝐂𝐃𝐒𝐂𝐎 𝐏𝐚𝐧𝐞𝐥 𝐀𝐩𝐩𝐫𝐨𝐯𝐞𝐬 𝐒𝐚𝐧𝐨𝐟𝐢'𝐬 𝐏𝐫𝐨𝐭𝐨𝐜𝐨𝐥 𝐀𝐦𝐞𝐧𝐝𝐦𝐞𝐧𝐭 𝐏𝐫𝐨𝐩𝐨𝐬𝐚𝐥 𝐅𝐨𝐫 𝐒𝐭𝐮𝐝𝐲 𝐨𝐟 𝐒𝐀𝐑𝟒𝟒𝟑𝟏𝟐𝟐 𝐢𝐧 𝐔𝐥𝐜𝐞𝐫𝐚𝐭𝐢𝐯𝐞 𝐂𝐨𝐥𝐢𝐭𝐢𝐬 📌The Subject Expert Committee (SEC) functional under the CDSCO has approved the drug major Sanofi's proposal for amendment of the clinical trial protocol titled, 'Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis (RESOLUTE). 📌This is a Phase 2 study evaluating SAR443122 versus placebo in moderate to severe Ulcerative Colitis. Dose selection for further development depends on efficacy, safety, and PK parameters. 📌SAR443122 is a novel, potent, and selective RIPK1 inhibitor for oral administration. SAR443122 selectively inhibits the kinase function of RIPK1 and inhibits the production of pro-inflammatory cytokines and necroptotic cell death that are thought to be detrimental to intestinal cell integrity. 📌After detailed deliberation, the committee recommended approval of the protocol amendment presented by the firm. #cdsco #sanofi #ulcerativecolitis

Gain control of your CRITICAL REAGENTS: Neutralizing anti-IDs can effectively compete for the binding site of therapeutic antibodies while preserving their ability to bind to target antigens. This innovative approach enables the utilization of anti-IDs as valuable tools for monitoring the localization and spread of drug mABs in biological samples. By capitalizing on the precise nature of antibody interactions (paratope-epitope recognition), this method proves instrumental in conducting pharmacokinetic studies efficiently. #criticalreagent #antiidiotypic #antibodies #antiid #antiego #mABs